This company trades under its own ticker, so it sits outside Biodatica’s pre-ticker window. The record stays here because its filings are real, but the feed leaves listed companies out unless you ask for them.
▲Phase II trial registered: Safety and Efficacy Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder Cancer
Momentum 93 out of 100, unchanged since the last recompute.
Accelerating: several high-weight events landed recently.
Runway (estimate)
—unknown
No disclosed raise on file, so there is nothing to model from.
Stage
Phase III
The furthest-along thing in the public record. Not a projection.
Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.
Grant to raise
Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.
Trial
PHASE2/PHASE3 registered
Dec 10, 2025
Choline Deficiency, Liver Injury · RECRUITING · sponsor: Protara Therapeutics · Study of Choline Chloride for Injection in Adolescent and Adult Patients With Intestinal Failure Receiving Long Term Parenteral Support
Lymphatic Malformation · RECRUITING · sponsor: Protara Therapeutics · Safety and Efficacy Study of Intracystic TARA-002 for the Treatment of Lymphatic Malformations in Participants 6 Months to Less Than 18 Years of Age
Non-muscle Invasive Bladder Cancer · RECRUITING · sponsor: Protara Therapeutics · Safety and Efficacy Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder Cancer
Non-muscle Invasive Bladder Cancer · COMPLETED · sponsor: Protara Therapeutics · Safety and Toxicity Study of Intravesical Instillation of TARA-002 in Adults with High-grade Non-muscle Invasive Bladder Cancer (Phase 1b)
Non-muscle Invasive Bladder Cancer · COMPLETED · sponsor: Protara Therapeutics · Safety and Toxicity Study of Intravesical Instillation of TARA-002 in Adults with High-grade Non-muscle Invasive Bladder Cancer (Phase 1a)
Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources
